Search Results - "Patel, Shreyaskumar"

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.

Authors: Patel, Shreyaskumar R. Reichardt, Peter

Source: Cancer (0008543X). Jul2021, Vol. 127 Issue 13, p2187-2195. 9p.

Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Authors: Patel, Shreyaskumar von Mehren, Margaret Reed, Damon R. et al.

Source: Cancer (0008543X). Aug2019, Vol. 125 Issue 15, p2610-2620. 11p.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Authors: Hensley, Martee L. Patel, Shreyaskumar R. von Mehren, Margaret et al.

Source: Gynecologic Oncology. Sep2017, Vol. 146 Issue 3, p531-537. 7p.

Chemotherapy for soft tissue sarcoma.

Authors: Ratan, Ravin Patel, Shreyaskumar R.

Source: Cancer (0008543X). Oct2016, Vol. 122 Issue 19, p2952-2960. 10p.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Authors: Schöffski, Patrick Chawla, Sant Maki, Robert G. et al.

Source: Lancet. 4/16/2016, Vol. 387 Issue 10028, p1629-1637. 9p.

Subjects: Drug efficacy, Eribulin, Dacarbazine, Liposarcoma, Soft tissue injuries, Therapeutics, Antineoplastic agents, Clinical trials, Comparative studies, Heterocyclic compounds, Ketones, Research methodology, Medical cooperation, Research, Soft tissue tumors, Survival analysis (Biometry), Evaluation research, Randomized controlled trials, Treatment effectiveness, Leiomyosarcoma, Tumor grading

Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?

Authors: Fan, Zhengfu Patel, Shreyaskumar Lewis, Valerae et al.

Source: Clinical Orthopaedics & Related Research®. Nov2015, Vol. 473 Issue 11, p3604-3611. 8p.

Long-term efficacy of imatinib for treatment of metastatic GIST.

Authors: Patel, Shreyaskumar¹ spatel@mdanderson.org

Source: Cancer Chemotherapy & Pharmacology. Aug2013, Vol. 72 Issue 2, p277-286. 10p.

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.

Authors: Park, Min S. Patel, Shreyaskumar R. Ludwig, Joseph A. et al.

Source: Cancer (0008543X). Nov2011, Vol. 117 Issue 21, p4939-4947. 9p.

Current and Emerging Pharmacological Treatments for Gastrointestinal Stromal Tumour.

Authors: Ganjoo, Kristen N. Patel, Shreyaskumar

Source: Drugs. 2011, Vol. 71 Issue 3, p321-330. 10p.

URL: 60572778

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Authors: DeMatteo, Ronald P. Ballman, Karla V. Antonescu, Cristina R. et al.

Source: Lancet. 3/28/2009, Vol. 373 Issue 9669, p1097-1104. 8p. 3 Graphs.

Subjects: Imatinib, Gastrointestinal stromal tumors, Immunological adjuvants, Gastrointestinal tumors, Prevention of surgical complications, Protein-tyrosine kinase inhibitors, Gastrointestinal system, Randomized controlled trials, Tumor treatment

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials

Authors: Patel, Shreyaskumar Zalcberg, John R.

Source: European Journal of Cancer. Mar2008, Vol. 44 Issue 4, p501-509. 9p.

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.

Authors: Jones, Robin L. Herzog, Thomas J. Patel, Shreyaskumar R. et al.

Source: Cancer Medicine. Jun2021, Vol. 10 Issue 11, p3565-3574. 10p.

TFCP2 Fusion-Positive Rhabdomyosarcomas: A Report of 10 Cases and a Review of the Literature.

Authors: Ginn, Madison P. Denu, Ryan A. Ingram, Davis R. et al.

Source: Cancers. May2025, Vol. 17 Issue 9, p1441. 24p.

Primary Intrathoracic Synovial Sarcoma: An Analysis of Outcomes of This Rare Disease.

Authors: Patel, Riddhi R. Bishop, Andrew J. Lazar, Alexander J. et al.

Source: Cancers. Mar2025, Vol. 17 Issue 5, p745. 15p.

Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort.

Authors: Nakazawa, Michael S Livingston, J Andrew Zarzour, Maria A et al.

Source: Rare Tumors. 8/4/2024, p1-9. 9p.

High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience.

Authors: Nasr, Lewis F. Zoghbi, Marianne Lazcano, Rossana et al.

Source: Cancers. May2024, Vol. 16 Issue 9, p1763. 17p.

Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors.

Authors: Denu, Ryan A. Joseph, Cissimol P. Urquiola, Elizabeth S. et al.

Source: Cancers. May2024, Vol. 16 Issue 9, p1707. 16p.

Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?

Authors: Thirasastr, Prapassorn Sutton, Thomas L. Joseph, Cissimol P. et al.

Source: Cancers. Mar2024, Vol. 16 Issue 5, p904. 16p.

STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.

Authors: Subbiah, Vivek McMahon, Caitlin Patel, Shreyaskumar et al.

Source: Journal of Hematology & Oncology. 2015, Vol. 8 Issue 1, p1-7. 7p.

Retrospective evaluation of the role of gemcitabine‐docetaxel in well‐differentiated and dedifferentiated liposarcoma.

Authors: Thirasastr, Prapassorn Lin, Heather Amini, Behrang et al.

Source: Cancer Medicine. Feb2023, Vol. 12 Issue 4, p4282-4293. 12p.